PharmaShots | Incisive News in 3 Shots

Subscribe Now

acute treatment

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bi...

May 19, 2021

Allergan's Ubrelvy (ubrogepant) Receives the US FDA's Approval for Acute Treatment of Migraine with or without Aura in Adults

Allergan's Ubrelvy (ubrogepant) Receives the US FDA's Approval for Acute Treatment of Migraine with or without Aura in Adults

December 26, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us